elmiron 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
N/0027 
Minor change in labelling or package leaflet not 
15/07/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0026/G 
This was an application for a group of variations. 
09/03/2022 
n/a 
B.II.b.1.a - Replacement or addition of a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
PSUSA/10614
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
pentosan polysulfate sodium (for centrally authorised 
product) 
R/0024 
Renewal of the marketing authorisation. 
11/11/2021 
11/01/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
elmiron in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
N/0023 
Minor change in labelling or package leaflet not 
21/07/2021 
29/09/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0022 
B.II.b.5.z - Change to in-process tests or limits 
04/05/2021 
n/a 
applied during the manufacture of the finished 
product - Other variation 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10614
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202006 
pentosan polysulfate sodium (for centrally authorised 
product) 
IA/0021 
A.5.b - Administrative change - Change in the name 
10/12/2020 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0019 
C.I.z - Changes (Safety/Efficacy) of Human and 
26/08/2020 
29/09/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
N/0018 
Minor change in labelling or package leaflet not 
22/04/2020 
29/09/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10614
Periodic Safety Update EU Single assessment - 
30/01/2020 
03/04/2020 
Refer to Scientific conclusions and grounds recommending 
/201906 
pentosan polysulfate sodium (for centrally authorised 
the variation to terms of the Marketing Authorisation(s)’ for 
product) 
PSUSA/10614/201906. 
N/0017 
Minor change in labelling or package leaflet not 
26/02/2020 
29/09/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0016/G 
This was an application for a group of variations. 
27/09/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASMF 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
N/0014 
Minor change in labelling or package leaflet not 
29/08/2019 
03/04/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10614
Periodic Safety Update EU Single assessment - 
27/06/2019 
23/08/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201812 
pentosan polysulfate sodium (for centrally authorised 
the variation to terms of the Marketing Authorisation(s)’ for 
product) 
PSUSA/10614/201812. 
N/0013 
Minor change in labelling or package leaflet not 
25/03/2019 
23/08/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0011 
B.II.e.1.a.1 - Change in immediate packaging of the 
15/02/2019 
n/a 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
PSUSA/10614
Periodic Safety Update EU Single assessment - 
17/01/2019 
n/a 
PRAC Recommendation - maintenance 
/201806 
pentosan polysulfate sodium (for centrally authorised 
product) 
IB/0010 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
16/11/2018 
31/01/2019 
SmPC, 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
life of the finished product - After first opening 
(supported by real time data) 
Labelling and 
PL 
IB/0008 
B.II.e.5.a.2 - Change in pack size of the finished 
14/08/2018 
31/01/2019 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
PSUSA/10614
Periodic Safety Update EU Single assessment - 
14/06/2018 
n/a 
PRAC Recommendation - maintenance 
/201712 
pentosan polysulfate sodium (for centrally authorised 
product) 
IB/0006 
B.II.f.z - Stability of FP - Other variation 
27/03/2018 
31/01/2019 
SmPC and PL 
IA/0005 
B.II.d.2.a - Change in test procedure for the finished 
27/02/2018 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
05/02/2018 
31/01/2019 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
N/0002 
Minor change in labelling or package leaflet not 
23/10/2017 
31/01/2019 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
N/0001 
Minor change in labelling or package leaflet not 
30/08/2017 
31/01/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
